Inovio Pharmaceuticals Inc. (INO): Price and Financial Metrics


Inovio Pharmaceuticals Inc. (INO): $3.84

-0.08 (-2.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 456

in industry

INO POWR Grades


  • INO scores best on the Value dimension, with a Value rank ahead of 33.78% of US stocks.
  • INO's strongest trending metric is Value; it's been moving down over the last 163 days.
  • INO ranks lowest in Momentum; there it ranks in the 4th percentile.

INO Stock Summary

  • With a price/sales ratio of 132.37, Inovio Pharmaceuticals Inc has a higher such ratio than 97.79% of stocks in our set.
  • With a year-over-year growth in debt of -55.58%, Inovio Pharmaceuticals Inc's debt growth rate surpasses merely 7.83% of about US stocks.
  • Revenue growth over the past 12 months for Inovio Pharmaceuticals Inc comes in at 208.81%, a number that bests 96.26% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Inovio Pharmaceuticals Inc, a group of peers worth examining would be CALA, CNCE, BCDA, KLDO, and DCPH.
  • Visit INO's SEC page to see the company's official filings. To visit the company's web site, go to www.inovio.com.

INO Valuation Summary

  • In comparison to the median Healthcare stock, INO's price/sales ratio is 2378.41% higher, now standing at 281.3.
  • INO's price/sales ratio has moved up 277.6 over the prior 243 months.
  • INO's price/earnings ratio has moved down 10.8 over the prior 243 months.

Below are key valuation metrics over time for INO.

Stock Date P/S P/B P/E EV/EBIT
INO 2021-08-31 281.3 3.6 -12.8 -13.0
INO 2021-08-30 281.3 3.6 -12.8 -13.0
INO 2021-08-27 285.9 3.6 -13.0 -13.2
INO 2021-08-26 283.3 3.6 -12.9 -13.1
INO 2021-08-25 274.8 3.5 -12.5 -12.7
INO 2021-08-24 272.8 3.5 -12.4 -12.6

INO Growth Metrics

    Its 2 year revenue growth rate is now at -92.18%.
  • Its 3 year cash and equivalents growth rate is now at -50.08%.
  • Its 2 year price growth rate is now at 146.38%.
Over the past 33 months, INO's revenue has gone down $23,965,674.

The table below shows INO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 6.516223 -229.0339 -221.0495
2021-06-30 6.460703 -256.7015 -141.7091
2021-03-31 6.455066 -205.3938 -188.2722
2020-12-31 7.41122 -177.979 -166.4112
2020-09-30 2.110127 -140.4999 -179.7348
2020-06-30 2.740812 -94.07501 -221.9968

INO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INO has a Quality Grade of D, ranking ahead of 14.67% of graded US stocks.
  • INO's asset turnover comes in at 0.012 -- ranking 168th of 186 Medical Equipment stocks.
  • POAI, EYES, and PETV are the stocks whose asset turnover ratios are most correlated with INO.

The table below shows INO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.012 1 -0.344
2021-03-31 0.012 1 -0.528
2020-12-31 0.017 1 -0.595
2020-09-30 0.006 1 -0.704
2020-06-30 0.010 1 -0.961
2020-03-31 0.013 1 -0.567

INO Price Target

For more insight on analysts targets of INO, see our INO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.71 Average Broker Recommendation 1.94 (Hold)

INO Stock Price Chart Interactive Chart >

Price chart for INO

INO Price/Volume Stats

Current price $3.84 52-week high $19.00
Prev. close $3.92 52-week low $3.46
Day low $3.78 Volume 1,665,398
Day high $3.98 Avg. volume 4,352,495
50-day MA $5.83 Dividend yield N/A
200-day MA $7.38 Market Cap 807.88M

Inovio Pharmaceuticals Inc. (INO) Company Bio


Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio leverages its optimized plasmid design and delivery technology to develop DNA medicines to potentially treat and prevent diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The company has more than 2,000 patients receiving Inovio DNA medicines in more than 7,000 clinical trial applications. Inovio’s corporate headquarters is in Plymouth Meeting, Pennsylvania with research & development and manufacturing facilities in San Diego, California. Dr. J. Joseph Kim serves as the company’s President and Chief Executive Officer.


INO Latest News Stream


Event/Time News Detail
Loading, please wait...

INO Latest Social Stream


Loading social stream, please wait...

View Full INO Social Stream

Latest INO News From Around the Web

Below are the latest news stories about Inovio Pharmaceuticals Inc that investors may wish to consider to help them evaluate INO as an investment opportunity.

Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | January 11, 2022

Better Vaccine Stock: Ocugen vs. Inovio Pharmaceuticals

Ocugen jumped into the race to develop a vaccine for COVID-19 by partnering up with Bharat Biotech, an India-based biotech company. Bharat Biotech ran a late-stage clinical trial for the vaccine in question, Covaxin, in India, and earned emergency use authorization (EUA) for it there.

Yahoo | January 11, 2022

Is 15% Potential Upside Good Enough to Risk Buying Inovio Stock? Analyst Weighs In

immunotherapy programs for infectious diseases. Most of the focus so far, however, has been on the Covid-19 program for INO-4800.

Marty Shtrubel on TipRanks | December 30, 2021

Inovio assumed with Hold at Jefferies with $6 target

Jefferies analyst Roger Song assumed coverage of Inovio Pharmaceuticals (INO -2.4%) with a Hold rating and price target (PT) of $6, down from $8. The analyst believes near-term stock movement will likely be driven by the company's COVID-19 program and he's cautious on the Phase 3 efficacy results of experimental...

Seeking Alpha | December 29, 2021

Vontobel Holding Ltd. Buys 77,800 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Vontobel Holding Ltd. raised its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 69.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 189,556 shares of the biopharmaceutical company’s stock after acquiring an additional 77,800 shares during the period. Vontobel Holding Ltd.’s holdings in Inovio Pharmaceuticals were worth $1,357,000 as of its most recent […]

Dakota Financial News | December 23, 2021

Read More 'INO' Stories Here

INO Price Returns

1-mo N/A
3-mo -43.45%
6-mo -54.82%
1-year -60.49%
3-year -24.71%
5-year -38.16%
YTD -23.05%
2021 -43.62%
2020 168.18%
2019 -17.50%
2018 -3.15%
2017 -40.49%

Continue Researching INO

Want to see what other sources are saying about Inovio Pharmaceuticals Inc's financials and stock price? Try the links below:

Inovio Pharmaceuticals Inc (INO) Stock Price | Nasdaq
Inovio Pharmaceuticals Inc (INO) Stock Quote, History and News - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7669 seconds.